alkaline hematin method

alkaline hematin method

An obsolete colorimetric technique for estimating the blood haemoglobin concentration based on the formation of hematin from haemoglobin, using 0.1 mol NaOH.
References in periodicals archive ?
The primary endpoint assessed the reduction in HMB compared to placebo as measured by the alkaline hematin method, an objective measurement of total menstrual blood loss (MBL) based on quantification of menstrual blood collected on sanitary products.
A response was defined as a menstrual blood loss volume of less than 80 mL and a 50% or greater reduction from baseline in menstrual blood loss volume during the last 35 days of treatment measured using the alkaline hematin method. On average, women receiving relugolix combination therapy experienced a highly significant 84.3% reduction in menstrual blood loss from baseline.
Patients were included if they were premenopausal, aged 18-50 years old, had prolonged bleeding in at least 4 of the last 6 menstrual periods, had menstrual blood loss of at least 80 mL by cycle by the alkaline hematin method, and had at least one discrete leiomyoma without a uterine size greater than 20 weeks.
The primary efficacy outcome of the study is a clinically-meaningful reduction in menstrual blood loss based upon the alkaline hematin method, a standardized centrally-assessed quantitative measurement of menstrual blood loss.
The double-blind, placebo-controlled clinical trial tested premenopausal women between 18 and 50 years old with cyclic (22 to 35 days) abnormal uterine bleeding in >=4 of the last 6 menstrual cycles, menstrual blood loss >=80 mL as measured by the alkaline hematin method over the first 8 days of menses, >=1 discrete uterine fibroid of any size and location observable by transvaginal ultrasound, follicle-stimulating hormone <=20 mIU/mL, and uterine volume <=20 weeks by exam.
The mean change in menstrual blood loss volume, as quantified using the alkaline hematin method, was -353 mL in the E2V/DNG arm vs.
(2) In this classic study, Hallberg and colleagues collected menstrual pads and tampons from the women and used the alkaline hematin method to estimate blood loss.
A response was defined as a menstrual blood loss volume of less than 80 mL and a 50% or greater reduction from baseline in menstrual blood loss volume during the last 35 days of the 24-week treatment period measured using the alkaline hematin method. On average, women receiving relugolix combination therapy experienced an 84.3% reduction in menstrual blood loss from baseline, a clinically relevant key secondary endpoint.
The primary endpoint in Phase 3 studies will be the same as in the Phase 2b study: reduction in uterine blood flow as measured by the alkaline hematin method.
Results from the second of two pivotal Phase 3 studies demonstrated at month six that elagolix, in combination with low-dose hormone therapy, reduced heavy menstrual bleeding with 76.2% of women with uterine fibroids achieving clinical response compared to placebo, as measured by the alkaline hematin method. Clinical response was defined as menstrual blood loss volume of less than 80 mL during month six and a 50% or greater reduction in menstrual blood loss volume from baseline to month six.
Results from the first of two pivotal Phase 3 studies demonstrated at month six that elagolix, in combination with low-dose hormone (add-back) therapy, reduced heavy menstrual bleeding with 68.5 percent (pless than0.001) of women with uterine fibroids achieving clinical response compared to placebo (8.7 percent), as measured by the alkaline hematin method. Clinical response was defined as menstrual blood loss volume of less than 80 mL during month six and a 50 percent or greater reduction in menstrual blood loss volume from baseline to month six.